ホーム › 多発性骨髄腫 › ミズーリ州 › St. Louis
St. Louis、MOにおける多発性骨髄腫の臨床試験
St. Louisとその周辺地域（約30マイル以内）の拠点で、多発性骨髄腫に関する24件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
被験者募集中第2相
- Washington University School Of Medicine, St Louis
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
被験者募集中第1/2相
- Washington University School of Medicine, St Louis
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
被験者募集中第1相
- Research Site, St Louis
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第2相
- Washington University School Of Medicine, St Louis
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
被験者募集中第4相
- Washington University School Of Medicine, St Louis
Collection of Tissue Samples for Cancer Research
被験者募集中観察研究
- Washington University - St. Louis, St Louis
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第2相
- Washington University School of Medicine, St Louis
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
被験者募集中第3相
- Washington University School of Medicine, St Louis
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第1/2相
- Research Site, St Louis
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
被験者募集中第2相
- GSK Investigational Site, Bridgeton · 15マイル先
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
被験者募集中第3相
- Mercy Infusion Center - Chippewa, St Louis
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- 他4件
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
被験者募集中第3相
- Research Site, St Louis
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
被験者募集中第2相
- Washington University School of Medicine, St Louis
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
被験者募集中第2相
- Washington University/Siteman Cancer Center, St Louis
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
被験者募集中第1相
- Washington University School of Medicine, St Louis
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
被験者募集中
- Washington University School of Medicine, St Louis
Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
被験者募集中第1相
- Washington University School of Medicine, St Louis
64Cu-LLP2A for Imaging Hematologic Malignancies
被験者募集中早期第1相健康なボランティア歓迎
- Washington University School of Medicine, St Louis
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
被験者募集中第3相
- Saint Louis Cancer and Breast Institute-South City, St Louis
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- 他5件
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
被験者募集中第1相
- Washington University School of Medicine, St Louis
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
被験者募集中
- Washington University School of Medicine, St Louis
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第1相
- Washington University /ID# 266972, St Louis
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
被験者募集中第3相
- Saint Louis University, St Louis
Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
被験者募集中第1相
- Washington University School of Medicine, St Louis
他の都市における多発性骨髄腫の試験
- New York City, NY60件の研究
- Boston, MA42件の研究
- Atlanta, GA41件の研究
- Houston, TX38件の研究
- Durham, NC37件の研究
- Nashville, TN32件の研究
- Denver, CO27件の研究
- Rochester, MN24件の研究
- Columbus, OH24件の研究
- Baldwin Park, CA23件の研究
- Chicago, IL22件の研究
- Seattle, WA22件の研究
St. Louisにおける他の研究
- 非小細胞肺癌73件の研究
- 乳がん64件の研究
- 転移性癌54件の研究
- 大腸癌50件の研究
- 前立腺がん46件の研究
- がん（全種類）46件の研究
- 肺がん39件の研究
- 卵巣がん38件の研究
- 膵臓がん33件の研究
- 子宮内膜がん29件の研究
- 頭頸部扁平上皮癌28件の研究
- 心不全26件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。